Comparison of pentamidine isethionate andtrimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia

Hughes, Walter T.; Feldman, Sandor; Chaudhary, Subhash; Ossi, Michael; Cox, Frederick; Sanyal, Shyamal K.

doi:10.1016/s0022-3476(78)80028-6

Cited by 225 publications

(85 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the past, the incidence of PCP has been reported to be about 15-21% among children with highrisk leukemia [1,2], and PCP affects 5-15% patients within 1 year after HSCT without prophylaxis [3]. Before the initiation of routine prophylaxis for PCP with trimethoprim-sulfamethoxazole (TMP-SMZ), a high infection rate of 43% was reported in subsets of pediatric oncology patients [2], and the mortality rate associated with PCP was 24% despite early diagnosis and appropriate treatment [4].…”

Section: Introductionmentioning

confidence: 99%

Intermittent oral trimethoprim/sulfamethoxazole on two non‐consecutive days per week is effective as Pneumocystis jiroveci pneumonia prophylaxis in pediatric patients receiving chemotherapy or hematopoietic stem cell transplantation

Ohata

Ohta

Hashii

et al. 2008

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Pneumocystis jiroveci pneumonia (PCP) is a serious complication in patients receiving chemotherapy or hematopoietic stem cell transplantation. Current recommendations for trimethoprim‐sulfamethoxazole (TMP‐SMZ) dosing as PCP prophylaxis in immunocompromised patients are based on either daily dosing or dosing three consecutive days per week. We report our experience of prophylaxis with TMP‐SMZ twice daily on two non‐consecutive days per week in 145 immunocompromised children with hematologic disorders, cancer, or metabolic disorders following chemotherapy or hematopoietic stem cell transplantation. There were no breakthrough cases of PCP. We therefore conclude our prophylaxis regimen is effective against PCP in immunocompromised children. Pediatr Blood Cancer 2009;52:142–144. © 2008 Wiley‐Liss, Inc.

show abstract

Section: Introductionmentioning

confidence: 99%

Intermittent oral trimethoprim/sulfamethoxazole on two non‐consecutive days per week is effective as Pneumocystis jiroveci pneumonia prophylaxis in pediatric patients receiving chemotherapy or hematopoietic stem cell transplantation

Ohata

Ohta

Hashii

et al. 2008

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Because of the low incidence of toxicity, co-trimoxazole has beenrecommended rather than pentamidineas the preferred drug for the treatment of PCP (2). The fixed combination of pyrimethamine (25 mg) and sulfadoxine (500 mg) (pyrimethamine-sulfadoxine)…”

Section: Co-trimoxazolementioning

confidence: 99%

Three Cases of Acquired Immunodeficiency Syndrome Complicated with Toxic Epidermal Necrolysis.

et al. 1991

View full text Add to dashboard Cite

“…Currently, there are two approved treatments: trimethoprim-sulfamethoxazole and pentamidine isethionate (10,14; N. C. Klein, F. P. Ducanson, T. H. Lenox, C. Forszpaniak, C. Scherer, H. Quentzel, and G. P. Wormser, Proc. 2nd Int.…”

mentioning

confidence: 99%

“…Conf. on AIDS, 1986); response rates are equivalent for the two regimens (10,15; Klein et al, Proc. 2nd Int.…”

mentioning

confidence: 99%

Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome

Mills

Leoung

Medina

et al. 1988

Antimicrob Agents Chemother

View full text Add to dashboard Cite

All patients with the acquired immunodeficiency syndrome treated for their first episode of Pneumocystis carinii pneumonia at San Francisco General Hospital between 1 April 1985 and 15 July 1985 were evaluated for their response to treatment with dapsone (100 mg/day) by mouth for 21 days. Of 44 patients evaluated, 18 were eligible for the study. Of these 18 patients, the conditions of 7 of them worsened or failed to improve during treatment with dapsone and they were considered treatment failures. These patients were changed to standard therapy after 4 to 8 days of dapsone therapy. The remaining 11 patients (61%) improved within 3 to 10 days after dapsone therapy was started. Side effects of dapsone therapy were noted in 6 of 11 patients (of these 11 patients, 5 had a rash, 1 had a rash and abnormal liver enzymes, and 1 had abnormal liver enzymes), but in none of the patients were these side effects severe enough to require the cessation of medication. Based on comparison with historical controls, oral dapsone therapy alone appeared to be less effective than standard therapy or the combination of dapsone plus trimethoprim for P. carinii pneumonia in patients with acquired immunodeficiency syndrome.

show abstract

Comparison of pentamidine isethionate andtrimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia

Cited by 225 publications

References 8 publications

Intermittent oral trimethoprim/sulfamethoxazole on two non‐consecutive days per week is effective as Pneumocystis jiroveci pneumonia prophylaxis in pediatric patients receiving chemotherapy or hematopoietic stem cell transplantation

Intermittent oral trimethoprim/sulfamethoxazole on two non‐consecutive days per week is effective as Pneumocystis jiroveci pneumonia prophylaxis in pediatric patients receiving chemotherapy or hematopoietic stem cell transplantation

Three Cases of Acquired Immunodeficiency Syndrome Complicated with Toxic Epidermal Necrolysis.

Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome

Contact Info

Product

Resources

About